However, tofacitinib, an oral JAK1/3 inhibitor, have failed to inhibit dsDNA-activated, STING-dependent IRF3 phosphorylation in an in vitro SAVI model due to pathogenic variants located outside STING ́s dimerization domain (40). This evidence concerns the gene STING1 and STING-associated vasculopathy with onset in infancy.